Akero Therapeutics (AKRO) stock was upgraded by Bank of America based on Phase 2 data the company shared for its liver disorder drug, efruxifermin. Read more here.
Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...
Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.
Andrew Cheng, the President and CEO of Akero Therapeutics, Inc. (NASDAQ:AKRO), has recently disposed of shares worth approximately $1.65 million. According to a Form 4 filing with the Securities and ...